RNL BIO Co., Ltd.
RNL BIO Co., Ltd. (RNL BIO) is a biotechnology company. It is principally engaged in the development and manufacture of stem cell therapy products. The company offers products in two categories endocrine remedies which includes anti diabetes mellitus, growth promotion and diet products, and bio safety products including anti-bacterial disinfectants. Its development pipeline includes stem cells products such as, lipostem-femoran for hip joint fractures, lipostem-DM for diabetes mellitus, astrostem for spinal cord injuries, vascostem for ischemic cardiac and cerebral infarctions, cancerstem for cancers and serum free mediums for stem cell proliferations. The company is headquartered in Seoul, Republic of Korea.The company reported revenues of (Won) KRW 46,648.15 million during the fiscal year ended December 2009, an increase of 70.46% over 2008. The operating profit of the company was KRW 64.19 million during the fiscal year 2009, a decrease of 94.64% from 2008. The net loss of the company was KRW 18,066.96 million during the fiscal year 2009, as compared to a net loss of KRW 7,448.22 million during 2008.